Lilly Q3 | search
Click here to view Lilly Q3 news from 60+ newspapers.
Bookmark or Share- Lilly Hit With Lower-Than-Expected Mounjaro and Zepbound Q3 Sales ...Lilly’s total Q3 revenue was $11.4 billion, up from $9.5 billion during the same period last year but behind analyst expectations of $12.1 billion. To partly explain its lower-than-expected results, the company pointed to a $2.83 billion charge in Q3, associated with its $3.2 billion acquisition of Morphic Holding in July 2024.
- Lilly reports Q3 2024 financial results highlighted by strong volume ..."Lilly had another strong growth quarter in Q3, with total revenue increasing by 42% after excluding divestiture activity in the same period last year," said David A. Ricks, Lilly chair and CEO. "While the growth of Mounjaro and Zepbound is impressive, we are equally proud of the 17% growth in non-incretin revenue, which includes our oncology ...
- Eli Lilly Stock Tumbles as Q3 Sales, Profits Fall Well ... - InvestopediaLilly swung to a profit of $970.3 million, or $1.07 per share, but still well below the $1.69 billion and $1.87 per share analysts were looking for. Adjusted EPS of $1.18 was barely half of the $2 ...
- Why Eli Lilly Stock Is Sinking Today | The Motley FoolLilly reported Q3 revenue of $11.4 billion, up 20% year over year. However, the consensus projection among analysts surveyed by LSEG was for revenue of $12.1 billion.
- Eli Lilly (LLY) earnings Q3 2024The drugmaker now expects full-year adjusted earnings of between $13.02 to $13.52 per share, down from previous guidance of $16.10 to $16.60 per share. Eli Lilly also lowered the high-end of its ...
More
